Cargando…
Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection
Human cytomegalovirus (HCMV) tegument protein pp150 is essential for the completion of the final steps in virion maturation. Earlier studies indicated that three pp150nt (N-terminal one-third of pp150) conformers cluster on each triplex (Tri1, Tri2A and Tri2B), and extend towards small capsid protei...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623180/ https://www.ncbi.nlm.nih.gov/pubmed/34835083 http://dx.doi.org/10.3390/v13112277 |
_version_ | 1784605870087208960 |
---|---|
author | Mitra, Dipanwita Hasan, Mohammad H. Bates, John T. Bidwell, Gene L. Tandon, Ritesh |
author_facet | Mitra, Dipanwita Hasan, Mohammad H. Bates, John T. Bidwell, Gene L. Tandon, Ritesh |
author_sort | Mitra, Dipanwita |
collection | PubMed |
description | Human cytomegalovirus (HCMV) tegument protein pp150 is essential for the completion of the final steps in virion maturation. Earlier studies indicated that three pp150nt (N-terminal one-third of pp150) conformers cluster on each triplex (Tri1, Tri2A and Tri2B), and extend towards small capsid proteins atop nearby major capsid proteins, forming a net-like layer of tegument densities that enmesh and stabilize HCMV capsids. Based on this atomic detail, we designed several peptides targeting pp150nt. Our data show significant reduction in virus growth upon treatment with one of these peptides (pep-CR2) with an IC(50) of 1.33 μM and no significant impact on cell viability. Based on 3D modeling, pep-CR2 specifically interferes with the pp150–capsid binding interface. Cells pre-treated with pep-CR2 and infected with HCMV sequester pp150 in the nucleus, indicating a mechanistic disruption of pp150 loading onto capsids and subsequent nuclear egress. Furthermore, pep-CR2 effectively inhibits mouse cytomegalovirus (MCMV) infection in cell culture, paving the way for future animal testing. Combined, these results indicate that CR2 of pp150 is amenable to targeting by a peptide inhibitor, and can be developed into an effective antiviral. |
format | Online Article Text |
id | pubmed-8623180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86231802021-11-27 Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection Mitra, Dipanwita Hasan, Mohammad H. Bates, John T. Bidwell, Gene L. Tandon, Ritesh Viruses Article Human cytomegalovirus (HCMV) tegument protein pp150 is essential for the completion of the final steps in virion maturation. Earlier studies indicated that three pp150nt (N-terminal one-third of pp150) conformers cluster on each triplex (Tri1, Tri2A and Tri2B), and extend towards small capsid proteins atop nearby major capsid proteins, forming a net-like layer of tegument densities that enmesh and stabilize HCMV capsids. Based on this atomic detail, we designed several peptides targeting pp150nt. Our data show significant reduction in virus growth upon treatment with one of these peptides (pep-CR2) with an IC(50) of 1.33 μM and no significant impact on cell viability. Based on 3D modeling, pep-CR2 specifically interferes with the pp150–capsid binding interface. Cells pre-treated with pep-CR2 and infected with HCMV sequester pp150 in the nucleus, indicating a mechanistic disruption of pp150 loading onto capsids and subsequent nuclear egress. Furthermore, pep-CR2 effectively inhibits mouse cytomegalovirus (MCMV) infection in cell culture, paving the way for future animal testing. Combined, these results indicate that CR2 of pp150 is amenable to targeting by a peptide inhibitor, and can be developed into an effective antiviral. MDPI 2021-11-15 /pmc/articles/PMC8623180/ /pubmed/34835083 http://dx.doi.org/10.3390/v13112277 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mitra, Dipanwita Hasan, Mohammad H. Bates, John T. Bidwell, Gene L. Tandon, Ritesh Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection |
title | Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection |
title_full | Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection |
title_fullStr | Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection |
title_full_unstemmed | Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection |
title_short | Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection |
title_sort | tegument protein pp150 sequence-specific peptide blocks cytomegalovirus infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623180/ https://www.ncbi.nlm.nih.gov/pubmed/34835083 http://dx.doi.org/10.3390/v13112277 |
work_keys_str_mv | AT mitradipanwita tegumentproteinpp150sequencespecificpeptideblockscytomegalovirusinfection AT hasanmohammadh tegumentproteinpp150sequencespecificpeptideblockscytomegalovirusinfection AT batesjohnt tegumentproteinpp150sequencespecificpeptideblockscytomegalovirusinfection AT bidwellgenel tegumentproteinpp150sequencespecificpeptideblockscytomegalovirusinfection AT tandonritesh tegumentproteinpp150sequencespecificpeptideblockscytomegalovirusinfection |